Literature DB >> 25522750

A 6-year follow-up study of adult patients with congenitally corrected transposition.

Mirta Koželj1, Marta Cvijić1, Pavel Berden2, Tomaž Podnar3.   

Abstract

The aims of this study were to assess the development of heart failure in patients with congenitally corrected transposition of the great arteries in a medium-term follow-up, to identify the impact of tricuspid regurgitation on the development of heart failure, and to determine the most reliable marker for its identification. The prospective 6-year follow-up study included 19 adult patients. All patients were evaluated clinically by the determination of N-terminal pro-hormone brain natriuretic peptide levels, exercise stress testing, echocardiography magnetic resonance, or CT. Among them, two patients died of heart failure. There was a decline in exercise capacity and systolic systemic ventricular function (p=0.011). Systemic ventricular ejection fraction decreased (48.3±13.7 versus 42.7±12.7%, p=0.001). Tissue Doppler imaging showed a decline in peak tricuspid systolic annular velocity (10.3±2.0 versus 8.3±2.5 cm/second, p=0.032) and peak tricuspid early diastolic annular velocity (14.6±4.3 versus 12.0±4.5 cm/second, p=0.048). The tricuspid regurgitation did not increase significantly. N-terminal pro-hormone brain natriuretic peptide levels increased (127.0 ng/L(82.3-305.8) versus 226.0 ng/L(112.5-753.0), p=0.022). Progressive exercise intolerance in congenitally corrected transposition of the great arteries appears to be driven mainly by a progression in systemic right ventricular dysfunction. Tricuspid regurgitation is likely to play a role, especially in patients with structural abnormalities of the tricuspid valve - Ebstein anomaly. The N-terminal pro-hormone brain natriuretic peptide levels and tissue Doppler parameters appear sensitive in detecting changes over time and may guide management.

Entities:  

Keywords:  Congenitally corrected transposition; adults; follow-up; heart failure

Mesh:

Substances:

Year:  2014        PMID: 25522750     DOI: 10.1017/S1047951114002479

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  1 in total

1.  B-type natriuretic peptide: powerful predictor of end-stage chronic heart failure in individuals with systolic dysfunction of the systemic right ventricle.

Authors:  Marketa Hegarova; Jaroslav Brotanek; Milos Kubanek; Radka Kockova; Janka Franekova; Vera Lanska; Ivan Netuka; Vojtech Melenovsky; Ivan Malek; Josef Kautzner
Journal:  Croat Med J       Date:  2016-08-31       Impact factor: 1.351

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.